Ipamorelin and tesamorelin are peptides that act through the body’s own growth hormone system. They do not directly introduce synthetic human growth hormone into the blood. Instead, they stimulate the pituitary through receptor signaling pathways, increasing the body’s own growth hormone release.
Ipamorelin: a highly selective growth hormone secretagogue
Ipamorelin is a synthetic pentapeptide and one of the first highly selective growth hormone secretagogues. It was developed to stimulate growth hormone release without significantly increasing cortisol, ACTH, prolactin, or appetite signals.
Ipamorelin was initially developed by Novo Nordisk and described in detail in a landmark 1998 paper in the European Journal of Endocrinology. It acts through the growth hormone secretagogue receptor (GHS-R1a), which is also linked to ghrelin signaling.
This selectivity has made ipamorelin particularly popular in anti-aging, recovery, and bodybuilding circles. Earlier secretagogues like GHRP-6 were associated with stronger appetite stimulation and broader hormonal effects, while ipamorelin was designed to produce a more targeted growth hormone response.
Human studies include trials in healthy volunteers. A Phase II randomized controlled trial involving 87 patients undergoing intestinal surgery is also underway, exploring whether the peptide can help restore normal postoperative intestinal motility. However, large human trials evaluating ipamorelin for muscle growth, anti-aging, or athletic recovery remain limited.
Tesamorelin: an FDA-approved fat-reduction peptide
Tesamorelin occupies a very different position in the evidence spectrum. It has full FDA approval and was originally developed as a synthetic analog of growth hormone-releasing hormone (GHRH).
Tesamorelin was approved in 2010 under the brand name Egrifta to reduce visceral abdominal fat in patients with HIV-associated lipodystrophy. In March 2025, the FDA approved a new formulation, EGRIFTA WR, which requires weekly rather than daily reconstitution.
Tesamorelin’s clinical evidence is far stronger than most peptides discussed in online recovery and biohacking communities. Two large Phase III trials involving 816 patients showed that tesamorelin significantly reduced visceral abdominal fat compared with placebo. A 2024 study in HIV patients receiving integrase inhibitor regimens reported results consistent with earlier trials.
What these two paths teach us
Ipamorelin and tesamorelin both act on the growth hormone axis, but one is still accumulating evidence while the other has completed regulatory approval. This reminds us: similar mechanisms do not equal similar evidence, and high popularity does not equal sufficient clinical validation.
Conclusion
When choosing growth hormone-related peptides, understanding evidence strength and approval status matters more than chasing online hype.